Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Multiple studies have demonstrated people with established schizophrenia have an increased dopamine synthesis capacity, and ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

Leal Therapeutics has secured yet another multi-million financing deal as the Worcester-based biotechnology startup has ...

Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push.  | Bristol Myers' $1.5 billion restructuring initiative that ...

Cognitive dysfunctions are common symptoms for Alzheimer's disease, schizophrenia, and other disorders of the central nervous ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

A new study finds poor attention spans in childhood, plus certain genes, could play a role in raising the risk for psychosis, ...